Compare Diagnos Laboratorium Utama Tbk. (DGNS) vs Reksa Dana Indeks Mandiri ETF Sri-Kehati (XMSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diagnos Laboratorium Utama Tbk. vs Reksa Dana Indeks Mandiri ETF Sri-Kehati — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp232 (market cap 319B), while Reksa Dana Indeks Mandiri ETF Sri-Kehati trades at Rp340 (market cap 49.81B). The key difference: Diagnos Laboratorium Utama Tbk. is far larger — about 6.4× Reksa Dana Indeks Mandiri ETF Sri-Kehati's market cap. Which is the better fit depends on your goals.
| DGNS | XMSK | |
|---|---|---|
Market Cap | 319B | 49.81B |
Indicative Equilibrium Price | 232 | — |
Indicative Equilibrium Volume | 2 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diagnos Laboratorium Utama Tbk.
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →
